These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 28692529)

  • 1. CYP2B6 genotypes and early efavirenz-based HIV treatment outcomes in Botswana.
    Gross R; Bellamy SL; Ratshaa B; Han X; Vujkovic M; Aplenc R; Steenhoff AP; Mosepele M; Moorthy G; Zuppa AF; Strom BL; Bisson GP
    AIDS; 2017 Sep; 31(15):2107-2113. PubMed ID: 28692529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Efavirenz Metabolism on Loss to Care in Older HIV+ Africans.
    Torgersen J; Bellamy SL; Ratshaa B; Han X; Mosepele M; Zuppa AF; Vujkovic M; Steenhoff AP; Bisson GP; Gross R
    Eur J Drug Metab Pharmacokinet; 2019 Apr; 44(2):179-187. PubMed ID: 30168000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of the associations of CYP2B6-516G>T polymorphisms with efavirenz-induced central nervous system side effects and virological outcome in HIV-infected adults.
    Cheng L; Wang Y; Li X; Feng W; Weng B; Yuan Q; Xia P; Sun F
    Pharmacogenomics J; 2020 Apr; 20(2):246-259. PubMed ID: 31636355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brief Report: CYP2B6 516G>T Minor Allele Protective of Late Virologic Failure in Efavirenz-Treated HIV-Infected Patients in Botswana.
    Vujkovic M; Bellamy SL; Zuppa AF; Gastonguay M; Moorthy GS; Ratshaa BR; Han X; Steenhoff AP; Mosepele M; Strom BL; Aplenc R; Bisson GP; Gross R
    J Acquir Immune Defic Syndr; 2017 Aug; 75(4):488-491. PubMed ID: 28481785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.
    Sinxadi PZ; Leger PD; McIlleron HM; Smith PJ; Dave JA; Levitt NS; Maartens G; Haas DW
    Br J Clin Pharmacol; 2015 Jul; 80(1):146-56. PubMed ID: 25611810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.
    Gallien S; Journot V; Loriot MA; Sauvageon H; Morlat P; Reynes J; Reliquet V; Chêne G; Molina JM;
    HIV Med; 2017 Sep; 18(8):537-545. PubMed ID: 28145050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda: Pooled Analysis of Two Prospective Studies.
    Chang JL; Lee SA; Tsai AC; Musinguzi N; Muzoora C; Bwana B; Boum Y; Haberer JE; Hunt PW; Martin J; Bangsberg DR; Kroetz DL; Siedner MJ
    AIDS Res Hum Retroviruses; 2018 Nov; 34(11):982-992. PubMed ID: 29973058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of CYP2B6 516G>T polymorphism on efavirenz/nevirapine toxicity. Implications on treatment outcomes: Lessons from Botswana.
    Maseng MJ; Tawe L; Thami PK; Moyo S; Kasvosve I; Novitsky V; Essex M; Russo G; Gaseitsiwe S; Paganotti GM
    Medicine (Baltimore); 2022 Apr; 101(17):e29066. PubMed ID: 35512066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.
    Haas DW; Kwara A; Richardson DM; Baker P; Papageorgiou I; Acosta EP; Morse GD; Court MH
    J Antimicrob Chemother; 2014 Aug; 69(8):2175-82. PubMed ID: 24729586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of mid-dose efavirenz concentrations and CYP2B6 genotype on viral suppression in patients on first-line antiretroviral therapy.
    Orrell C; Bienczak A; Cohen K; Bangsberg D; Wood R; Maartens G; Denti P
    Int J Antimicrob Agents; 2016 Jun; 47(6):466-72. PubMed ID: 27211824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms in cytochrome P450 are associated with extensive efavirenz pharmacokinetics and CNS toxicities in an HIV cohort in Botswana.
    Vujkovic M; Bellamy SL; Zuppa AF; Gastonguay MR; Moorthy GS; Ratshaa B; Han X; Steenhoff AP; Mosepele M; Strom BL; Bisson GP; Aplenc R; Gross R
    Pharmacogenomics J; 2018 Sep; 18(5):678-688. PubMed ID: 29855606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2B6 haplotype and biological factors responsible for hepatotoxicity in HIV-infected patients receiving efavirenz-based antiretroviral therapy.
    Manosuthi W; Sukasem C; Lueangniyomkul A; Mankatitham W; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
    Int J Antimicrob Agents; 2014 Mar; 43(3):292-6. PubMed ID: 24359841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.
    Wyen C; Hendra H; Siccardi M; Platten M; Jaeger H; Harrer T; Esser S; Bogner JR; Brockmeyer NH; Bieniek B; Rockstroh J; Hoffmann C; Stoehr A; Michalik C; Dlugay V; Jetter A; Knechten H; Klinker H; Skaletz-Rorowski A; Fätkenheuer G; Egan D; Back DJ; Owen A;
    J Antimicrob Chemother; 2011 Sep; 66(9):2092-8. PubMed ID: 21715435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients.
    Mhandire D; Lacerda M; Castel S; Mhandire K; Zhou D; Swart M; Shamu T; Smith P; Musingwini T; Wiesner L; Stray-Pedersen B; Dandara C
    OMICS; 2015 Sep; 19(9):553-62. PubMed ID: 26348712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma levels in adult HIV patients.
    Bienvenu E; Swart M; Dandara C; Ashton M
    Antiviral Res; 2014 Feb; 102():44-53. PubMed ID: 24316028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti.
    Haas DW; Severe P; Jean Juste MA; Pape JW; Fitzgerald DW
    J Antimicrob Chemother; 2014 Aug; 69(8):2187-90. PubMed ID: 24695352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.
    Dhoro M; Zvada S; Ngara B; Nhachi C; Kadzirange G; Chonzi P; Masimirembwa C
    BMC Pharmacol Toxicol; 2015 Mar; 16():4. PubMed ID: 25889207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of Cytochrome P450 2B6 Single Nucleotide Polymorphism in an HIV-Positive Cohort in Jos, Nigeria: Implication for HIV Therapy.
    Isaac AO; Wetkos DD; Oche AO; Godwin I; Phyllis K; John AC
    Niger J Clin Pract; 2020 Dec; 23(12):1736-1743. PubMed ID: 33355828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin.
    Soeria-Atmadja S; Österberg E; Gustafsson LL; Dahl ML; Eriksen J; Rubin J; Navér L
    PLoS One; 2017; 12(9):e0181316. PubMed ID: 28886044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline predictors of efavirenz-containing antiretroviral regimen adverse experiences.
    Sonenthal PD; Ratshaa B; Chimbengo G; Rantleru T; Ngoni T; Barenbaum S; Platoff R; Steenhoff AP; Gross R
    Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):773-7. PubMed ID: 24664872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.